Who We Are
We are an early stage Anglo-American biotech company with a novel and proprietary platform targeting viral protein synthesis.
Our drugs are designed to be effective for treatment resistant infections and rapidly mutating pathogens.
Our drugs are designed to treat influenza, hepatitis B, smallpox, COVID-19, and a further pipeline of viral pathogens.
Our development and manufacturing processes are proven, faster and more cost-efficient than those for biologics and vaccines.
Our drugs will be easy to administer and will be suitable for use as post-exposure prophylaxis.
Meet The Team
Chris is a pharma executive with outstanding commercialization and business leadership experience providing commercial input into R&D strategy from pre-clinical, through to Phase III in virology, immunology and oncology fields, while in global leadership positions at Gilead, Amgen, AstraZeneca, Bristol Myers Squibb, Merck and others.
Boris accumulated extensive experience in building, developing and managing companies in cutting-edge industries, including biotech, chemical, nanotechnology, and advanced manufacturing. His strategic leadership been pivotal in delivering several full-value public listings and numerous other exit strategies, with successful commercialization of assets.
Emre is a physician scientist and an expert on biological and advanced therapy medicines, including RNA, gene therapies and ASO drugs, who has been in medical leadership at Orphazyme, Akcea, Fresenius Kabi and Sanofi Genzyme. Emre also sits on the British Pharmacopoeia Commission and is the Vice-Chair of its Expert Advisory Group on Biological and Biotechnological Products.
Julia a highly experienced executive leader in pharmaceutical and CRO-side of drug development and with extensive expertise in building, developing and growing international businesses, both in private and large-cap public company settings in clinical development, biotech and market access sectors. She has substantial experience in investor-side biotech funding.
Traction & Accomplishments
Product Development
- We have patents covering our drug development methodology and RAPTOR-AI™, our AI-assistance package.
- We have drug structures designed for several viruses and virus families.
- We have cost effective pre-clinical and clinical development and business plans to maximize return while minimizing risks.
Manufacturing and Distribution
- Our contract manufacturing and development partners for our Active Pharmaceutical Ingredient (API) and pharmaceutical formulation are secured.
- Our chemical manufacturing process is 30x-50x more cost efficient compared to biologics.
Investor Protection
Patents and Intellectual Property
- Our attorneys are Morrison and Foerster www.mofo.com
- Our primary trade secrets and intellectual property are protected with appropriate patents.
- Further patents will be applied for when appropriate for each NCE or other new IP.
Financial Integrity
- Our appointed auditors are Baker Tilly www.bakertilly.com
Business Model Revenue Streams
Manufacturing, laboratory, pre-clinical, and clinical operations will be outsourced to reliable, carefully selected contract organizations with a strong expertise in RNA-based therapies as well as target indications.
Core Business Assets
- Ownership of the RAPTOR-AI™ platform: patent protected scientific method and know-how
- In-house generated new chemical entities, expertise and further IP generation
Drug Development Through To Marketing Authorisation
- Use of CROs and contractors to outsource specialist skills required, e.g., preclinical studies, manufacturing
- Develop in house teams in medium to long term
Flexible range of options for drug commercialization
- Prioritize and target major markets – US, EU5 (including the UK), rest of EU, JAPAC, LATAM
- Combination of own sales & marketing and licensing agreements depending on local environment
Offices in Raleigh, NC and Cambridge, UK
- Current footprint sufficient for transatlantic operations
- Expand as and when necessary
